Loading
IARC estimates 26,268 new cancer cases and 15,848 cancer deaths in Afghanistan in 2024; the commonest new cancers are breast, stomach and colorectum. This page is assembled automatically from OnCo's data, and says what OnCo does not yet hold.
Built partly from other countries' data. IARC's method code for Afghanistan's incidence estimate is 5: rates based on incidence estimates or registry data from neighbouring countries. Read the figures as a regional estimate, not a count.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 4,342 | 34.6 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Stomach | 1,913 | 10.8 | Gastric & gastro-oesophageal junction cancer |
| Colorectum | 1,882 | 9.5 | Colorectal cancer |
| Leukaemia | 1,333 | 3.8 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Brain, central nervous system | 1,302 | 4.5 | Glioma & glioblastoma |
| Trachea, bronchus and lung | 1,241 | 6.7 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Prostate | 995 | 14.8 | Prostate cancer |
| Non-Hodgkin lymphoma | 833 | 3.3 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Liver and intrahepatic bile ducts | 822 | 4.2 | Hepatocellular carcinoma |
| Cervix uteri | 790 | 6.4 | Cervical cancer |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Breast | 1,868 | 15.8 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Stomach | 1,583 | 9.3 | Gastric & gastro-oesophageal junction cancer |
| Trachea, bronchus and lung | 1,082 | 6.1 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Brain, central nervous system | 1,009 | 3.7 | Glioma & glioblastoma |
| Colorectum | 961 | 5.1 | Colorectal cancer |
| Leukaemia | 833 | 2.5 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Liver and intrahepatic bile ducts | 752 | 4.0 | Hepatocellular carcinoma |
| Oesophagus | 681 | 3.9 | Oesophageal cancer |
| Prostate | 573 | 8.7 | Prostate cancer |
| Cervix uteri | 456 | 3.8 | Cervical cancer |
No trial record in OnCo lists a site in Afghanistan. OnCo reads sites from ClinicalTrials.gov; studies registered only elsewhere are searchable through the WHO International Clinical Trials Registry Platform.
OnCo holds no institution, company or person in Afghanistan.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Afghanistan is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
A deep dive for Afghanistan is ranked 51 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.